Ovid Therapeutics
OVID
74 hedge funds and large institutions have $35.4M invested in Ovid Therapeutics in 2024 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 23 increasing their positions, 24 reducing their positions, and 21 closing their positions.
188% more call options, than puts
Call options by funds: $23K | Put options by funds: $8K
4% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 24
6% less ownership
Funds ownership: 70.87% → 64.87% (-6%)
9% less funds holding
Funds holding: 81 → 74 (-7)
33% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 21
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
77% less capital invested
Capital invested by funds: $153M → $35.4M (-$117M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$4.14M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$3.9M |
| 3 |
MAP
Madison Avenue Partners
New York
|
+$1.21M |
| 4 |
Wells Fargo
San Francisco,
California
|
+$856K |
| 5 |
State Street
Boston,
Massachusetts
|
+$553K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$18.7M |
| 2 |
BOCH
Blue Owl Capital Holdings
New York
|
-$2.64M |
| 3 |
BlackRock
New York
|
-$565K |
| 4 |
TA
TLS Advisors
Miami,
Florida
|
-$541K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$410K |
OVID Hedge Fund Activity: Q2 2024 in Review
74 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Ovid Therapeutics (OVID) for Q2 2024, worth a combined $35.4M — down 77% from $153M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of OVID and 14 opened new positions — a net loss of 7 holders — while 24 trimmed existing stakes and 23 added.
The largest buyer was Kennedy Capital Management, opening a new position worth an estimated $4.14M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $18.7M sold.
- 74 institutional investors held Ovid Therapeutics (OVID) as of Q2 2024, down from 81 in Q1 2024.
- Funds reported $35.4M of Ovid Therapeutics stock for Q2 2024, down 77% quarter-over-quarter.
- 14 funds opened new Ovid Therapeutics positions in Q2 2024 and 21 closed out, a net change of -7 holders.
- The largest Ovid Therapeutics buyer in Q2 2024 was Kennedy Capital Management, an estimated $4.14M added.
- The largest Ovid Therapeutics seller in Q2 2024 was EcoR1 Capital, an estimated $18.7M sold.
Based on aggregated 13F filings for Q2 2024.